Apnimed closed its initial public offering on July 30, 2026 at $16.00 a share and finished its first ten trading days up roughly 75%, near $28. The market is voting on a single, dated bet: whether the FDA approves Oxnimbi - a once-daily, fixed-dose pill combining a novel anti-muscarinic (aroxybutynin) and a selective norepinephrine reuptake inhibitor (atomoxetine) - for adult obstructive sleep apnea on the PDUFA goal date of February 28, 2027. Two Phase 3 trials, LunAIRo and SynAIRgy, enrolled roughly 1,300 patients across the United States and Canada, hit their primary apnea-hypopnea-index (AHI) endpoint with high statistical significance, and showed no drug-related serious adverse events. The NDA was submitted in April 2026 and accepted for review by the FDA in July 2026, on the standard 10-month cycle. The first read on the story is that this is a textbook late-stage biotech IPO: a one-asset, one-PDUFA company priced for a binary event ten months out.
The second read is more interesting, and it is what the prospectus forces the model to confront. The same prospectus carries an explicit "substantial doubt about our ability to continue as a going concern" paragraph tied to the unaudited March 31, 2026 balance sheet ($46.9 million of cash, $329.6 million of accumulated deficit), and the prospectus's pro-forma-as-adjusted walk - counting the SASS Disposition's $100.0 million Closing Payment received in April 2026, the $46.1 million net proceeds from the first tranche of an up-to-$150 million HCR OSA SPV term loan, and $173.6 million in IPO net proceeds - produces an estimated cash position in the mid-$340 millions and a stated runway through June 2028. Q1 2026 reported a striking $67.7 million GAAP net income, but $74.8 million of that came from a one-time ASC 606 cumulative-catch-up revenue adjustment triggered by the SASS Disposition, not from product sales; there are no product sales. Investors at $28 are paying $1.12 billion of equity value for a company that has recognized cumulative revenue of roughly $131 million over the last two years, all of it tied to a single now-terminated related-party services agreement that just got unwound.
The market is pricing three things, in this order: the PDUFA binary, the runway math, and the strategic-bet cleanup. The first is binary and will resolve on a fixed date. The second is mechanical: with cash around $346 million after the IPO, $50 million of term-loan face already drawn, a Tranche B milestone of $50 million that triggers on FDA approval, and a guided runway through June 2028, the company can either self-fund a 2027 launch alone or come back to the capital markets - and that decision sits entirely on the February 2027 PDUFA result. The third is where this quarter's print is most consequential: the SASS Disposition monetized a four-year-old joint venture with Shionogi for $100 million of cash, $50 million of milestone potential, and an Earnout, all in exchange for the rights to a related Shionogi-led discovery program that had produced the bulk of Apnimed's prior revenue. The Shionogi Right-of-First-Negotiation Agreement was terminated in April 2026, the $57.1 million ROFN deposit liability that had been sitting on the books was released into other income, and a $38.5 million convertible-note obligation converted to common at the IPO. The company arrived at the public market with a single asset, a single binary event, and a balance sheet freshly cleaned up to fund the year ahead. The thesis is the PDUFA. The runway is the bridge. The cleanup is what makes the bridge possible.